Sclerotherapy Global Market Report 2025

The sclerotherapy market size has grown strongly in recent years. It will grow from $1.14 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth during the historic period can be attributed to the rising prevalence of varicose veins, an increasing aging population, growing demand for minimally invasive procedures, improved healthcare infrastructure, greater awareness of aesthetic treatments, and expanding insurance coverage for vein-related conditions.

The sclerotherapy market size is expected to see strong growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be linked to the increasing adoption of minimally invasive procedures, the rising prevalence of chronic venous disorders, growing awareness of cosmetic vein treatments, expanding access to specialized vein clinics, increased healthcare expenditure in emerging markets, and supportive regulatory initiatives promoting outpatient treatments. Key trends in the forecast period include advancements in foam-based formulations, integration of ultrasound-guided techniques, adoption of minimally invasive procedures, development of personalized treatment plans, use of AI for diagnostic precision, enhanced post-procedure recovery protocols, and the expansion of outpatient vein clinics.

The growing prevalence of varicose veins and spider veins is anticipated to drive the expansion of the sclerotherapy market. Varicose and spider veins are enlarged, twisted, or damaged veins that are visible under the skin, primarily caused by poor blood circulation, particularly in the legs. This rise in prevalence is largely attributed to modern lifestyles, where people spend long hours sitting or standing, often due to work-related habits. Sclerotherapy addresses this issue by using targeted injections of a solution that seals off damaged veins, improving blood flow and the appearance of the skin. For example, a January 2024 report from the National Center for Biotechnology Information (NCBI) noted that in Brazil, 47.6% of the population suffered from varicose veins, with women having a higher prevalence (50.9%) compared to men (37.9%). As such, the increasing occurrence of varicose and spider veins is expected to significantly boost the growth of the sclerotherapy market.

The rising healthcare expenditure is driving the growth of the sclerotherapy market. Healthcare expenditure refers to the total spending on medical services, treatments, and health-related resources within a country or healthcare system. The rise in healthcare spending is largely attributed to the increasing costs of advanced medical technologies, which, while improving diagnosis and treatment, require substantial investment in development, equipment, and specialized personnel. This financial support enhances access to specialized treatments such as sclerotherapy, ensuring availability of medical staff and cutting-edge equipment. For instance, the Office for National Statistics in the UK reported in May 2024 that healthcare expenditure in the UK reached approximately \$421.32 billion (£317 billion) in 2024, marking a 6.5% increase compared to 2023. Therefore, the upward trend in healthcare expenditure is expected to continue fueling the growth of the sclerotherapy market.

Major companies in the sclerotherapy market are forming strategic partnerships to enhance their research capabilities and broaden their product offerings. These collaborations aim to strengthen their presence through shared expertise and global distribution networks. Advanced, minimally invasive treatments for varicose veins, such as sclerotherapy, laser therapy, and radiofrequency ablation, offer effective solutions to close or remove damaged veins with minimal pain, quick recovery, and fewer complications. For example, in February 2025, Aakash Healthcare, a specialty hospital in India, partnered with Medtronic plc, a US-based healthcare company, to launch a specialized vein clinic. This clinic offers advanced, minimally invasive treatments for varicose veins and other vein-related conditions, providing patients with faster recovery and long-term health benefits. Additionally, the clinic offers personalized treatment plans and post-treatment care, ensuring a comprehensive approach to vein health and overall well-being.

Major players in the sclerotherapy market are Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Olympus Corporation, Smith & Nephew plc, Teleflex Incorporated, Cook Medical, Merz Pharma GmbH & Co. KGaA, AngioDynamics Inc., Bioniche Pharma Group Ltd, Omega Pharmaceuticals Pvt. Ltd., Endo-Flex, Kreussler, Vascular Solutions, Inc., LGM Pharma, BTG International Ltd.

North America was the largest region in the sclerotherapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sclerotherapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sclerotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Sclerotherapy is a minimally invasive procedure used to treat varicose and spider veins by injecting a concentrated solution (sclerosant) directly into the affected veins. The sclerosant irritates the vein lining, causing it to collapse, scar, and eventually be reabsorbed by the body. Over time, the treated veins fade, and blood flow is redirected through healthier vessels.

The main types of sclerotherapy are liquid sclerotherapy, foam sclerotherapy, and ultrasound-guided sclerotherapy. Liquid sclerotherapy involves injecting a solution into the affected veins and is used to treat varicose and spider veins. The procedure employs various agents, including detergents, chemical irritants, and osmotic agents. These are used for applications such as varicose veins, spider veins, and hemorrhoids, serving various end users such as hospitals, ambulatory surgical centers, specialty clinics, and others.

The sclerotherapy market research report is one of a series of new reports that provides sclerotherapy market statistics, including the sclerotherapy industry global market size, regional shares, competitors with the sclerotherapy market share, detailed sclerotherapy market segments, market trends, and opportunities, and any further data you may need to thrive in the sclerotherapy industry. This sclerotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sclerotherapy market consists of revenues earned by entities by providing services such as spider vein removal, cosmetic vein treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The sclerotherapy market also includes sales of polidocanol asclera, hypertonic saline, sodium tetradecyl sulfate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.